These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 16894389

  • 21. Tumor Lysis Syndrome.
    Barbar T, Jaffer Sathick I.
    Adv Chronic Kidney Dis; 2021 Sep; 28(5):438-446.e1. PubMed ID: 35190110
    [Abstract] [Full Text] [Related]

  • 22. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress.
    Matuszkiewicz-Rowinska J, Malyszko J.
    Kidney Blood Press Res; 2020 Sep; 45(5):645-660. PubMed ID: 32998135
    [Abstract] [Full Text] [Related]

  • 23. Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia.
    Agha-Razii M, Amyot SL, Pichette V, Cardinal J, Ouimet D, Leblanc M.
    Clin Nephrol; 2000 Jul; 54(1):59-63. PubMed ID: 10939758
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
    Mughal TI, Ejaz AA, Foringer JR, Coiffier B.
    Cancer Treat Rev; 2010 Apr; 36(2):164-76. PubMed ID: 20031331
    [Abstract] [Full Text] [Related]

  • 27. Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma. Description of 2 cases and a review of the literature on prevention and management.
    Veenstra J, Krediet RT, Somers R, Arisz L.
    Neth J Med; 1994 Nov; 45(5):211-6. PubMed ID: 7830847
    [Abstract] [Full Text] [Related]

  • 28. Marked hyperuricemia with acute renal failure: need to consider occult malignancy and spontaneous tumour lysis syndrome.
    Agnani S, Gupta R, Atray NK, Vachharajani TJ.
    Int J Clin Pract; 2006 Mar; 60(3):364-6. PubMed ID: 16494656
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G, Giordano M, Malaguarnera M.
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [Abstract] [Full Text] [Related]

  • 31. [The pathophysiology, clinical signs and therapy of urate nephropathy].
    Méhes L, Udvardy M, Szász R, Rejto L.
    Orv Hetil; 2007 Apr 22; 148(16):745-8. PubMed ID: 17437951
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR, Burry LD, Cheng DK.
    Pharmacotherapy; 2007 Jan 22; 27(1):111-21. PubMed ID: 17192165
    [Abstract] [Full Text] [Related]

  • 34. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD, Ajiboye VO.
    J Oncol Pharm Pract; 2010 Sep 22; 16(3):205-13. PubMed ID: 19923162
    [Abstract] [Full Text] [Related]

  • 35. Managing tumor lysis syndrome.
    Greguska C.
    JAAPA; 2021 Jan 01; 34(1):10-13. PubMed ID: 33315730
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tumor lysis syndrome: a systematic review of case series and case reports.
    Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, Hasan S, Varon J.
    Postgrad Med; 2012 Mar 01; 124(2):92-101. PubMed ID: 22437219
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.